Biomerica, Inc. (BMRA)
NASDAQ: BMRA · Real-Time Price · USD
0.5640
-0.0030 (-0.53%)
Apr 1, 2025, 10:38 AM EDT - Market open
Biomerica Employees
Biomerica had 64 employees as of May 31, 2024. The number of employees increased by 2 or 3.23% compared to the previous year.
Employees
64
Change (1Y)
2
Growth (1Y)
3.23%
Revenue / Employee
$87,156
Profits / Employee
-$87,578
Market Cap
10.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
BMRA News
- 4 weeks ago - Biomerica Achieves IVDR Certification in the European Union for Food Intolerance Tests Targeting Crohn's Disease and Ulcerative Colitis - GlobeNewsWire
- 5 weeks ago - Biomerica's inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal - GlobeNewsWire
- 2 months ago - Biomerica Stock Trades 200% Higher After Prostate Screening Test Receives Approval - Benzinga
- 2 months ago - United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer - GlobeNewsWire
- 2 months ago - Biomerica Reports Second Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 4 months ago - Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis - GlobeNewsWire
- 5 months ago - Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements - GlobeNewsWire
- 5 months ago - Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain - GlobeNewsWire